Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,140 matching trials from the live ClinicalTrials.gov search.
Conditions
Influenza, Human, COVID-19
Interventions
Comirnaty, Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,442,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Conditions
Influenza
Interventions
QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
2,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
36
States / cities
Anaheim, California • Redding, California • San Diego, California + 29 more
Conditions
Vaccination, Influenza
Interventions
Local educational information, National educational information
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
6 Months and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

A Study of the Pharmacology of Tamiflu in Pregnancy

NCT01203527
Conditions
H1N1 Influenza Treatment During Pregnancy
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
14 Years to 45 Years · Female only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
4
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression

NCT01733056
Conditions
Immunosuppression
Interventions
Flu Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Pneumonia, Viral
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
New York, New York
Conditions
Influenza
Interventions
Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
6
States / cities
Colorado Springs, Colorado • Council Buffs, Iowa • Metairie, Louisiana + 3 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults

NCT00294099
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunologic Response to Influenza Vaccination in Children and Adolescents

NCT03614975
Conditions
Influenza, Human, Immune Response
Interventions
Flucelvax inactivated influenza vaccine, Fluzone inactivated influenza vaccine
Biological
Lead sponsor
Richard Zimmerman MD
Other
Eligibility
4 Years to 20 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Influenza
Interventions
VAX161 [STF2.HA5 H5N1]
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Intranasal LAIV Mucosal Immunity Examination

NCT07093281
Conditions
Impact of Vaccination
Interventions
Live Attenuated Influenza Vaccine
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
2 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Influenza
Interventions
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Mesa, Arizona
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Cocooning Immunization Strategy With Influenza Vaccine

NCT00570037
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
544 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel

NCT05163730
Conditions
COVID-19, Influenza A, Influenza Type B
Interventions
COVID-19/ Flu A&B Rapid Panel
Device
Lead sponsor
Abbott Rapid Diagnostics Jena GmbH
Industry
Eligibility
Not listed
Enrollment
2,472 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Easley, South Carolina
Conditions
Influenza
Interventions
Amantadine, Ribavirin, Oseltamivir, Oseltamivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
69
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 58 more
Completed Phase 2 Interventional Results available

H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

NCT00992433
Conditions
Influenza
Interventions
Inactivated Influenza H1N1 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 3 more
Conditions
Influenza
Interventions
Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Recruiting Phase 2 Interventional Accepts healthy volunteers

Systems Investigation of Vaccine Responses in Aging and Frailty

NCT05291676
Conditions
Influenza
Interventions
Fluzone, Fluad
Biological
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reverse Genetic H9N2 Influenza Vaccine Study in Adults

NCT01320696
Conditions
Influenza
Interventions
Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
5
States / cities
Huntsville, Alabama • Melbourne, Florida • Peoria, Illinois + 2 more
Recruiting No phase listed Observational Accepts healthy volunteers

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

NCT04579588
Conditions
Corona Virus Infection, Flu Vaccine, Immunity
Interventions
Flu shot
Biological
Lead sponsor
Stanford University
Other
Eligibility
9 Years to 64 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Influenza A
Interventions
MHAA4549A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
38
States / cities
Athens, Alabama • Costa Mesa, California • Fountain Valley, California + 32 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Bone Marrow and Peripheral Blood Immune Responses Study

NCT05616546
Conditions
Influenza
Interventions
Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strengthening Intentions

NCT07222774
Conditions
Influenza Vaccination, Behavior And Behavior Mechanism
Interventions
Experimental
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Flublok or Fluzone With Advax-CpG55.2 or AF03

NCT03945825
Conditions
Influenza, Influenza Immunisation
Interventions
AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more